PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för linsitinib. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

28 hits

Bibliografisk träff 2023-09-22

Potential involvement of the bone marrow in experimental Graves' disease and thyroid eye disease.

Gulbins A, Horstmann M, Keitsch S, Soddemann M, Wilker B, Wilson GC, Zeidan R, Hammer GD, Daser A, Bechrakis NE, Görtz GE, Eckstein A.

Front Endocrinol (Lausanne) · research support, non-u.s. gov't; research-article; journal article · DOI 10.3389/fendo.2023.1252727

Bibliografisk träff 2023-09-13

Accumulation of endogenous adenosine improves cardiomyocyte metabolism via epigenetic reprogramming in an ischemia-reperfusion model.

Wang P, Gao R, Wu T, Zhang J, Sun X, Fan F, Wang C, Qian S, Li B, Zou Y, Huo Y, Fassett J, Chen Y, Ge J, Sun A.

Redox Biol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1016/j.redox.2023.102884

Bibliografisk träff 2023-06-26

Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease.

Gulbins A, Horstmann M, Daser A, Flögel U, Oeverhaus M, Bechrakis NE, Banga JP, Keitsch S, Wilker B, Krause G, Hammer GD, Spencer AG, Zeidan R, Eckstein A, Philipp S, Görtz GE.

Front Endocrinol (Lausanne) · research support, non-u.s. gov't; research-article; journal article · DOI 10.3389/fendo.2023.1211473

Bibliografisk träff 2023-04-23

IGF-1 receptor inhibitor OSI-906 reduces growth in nestlings of a wild passerine.

Lodjak J, Mägi M, Verhulst S.

Gen Comp Endocrinol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ygcen.2023.114293

Bibliografisk träff 2023-02-01

Increased Fat Graft Survival by Promoting Adipocyte Dedifferentiation.

Chai Y, Jia X, Zhu J, Jiang C, Yin N, Li F.

Aesthet Surg J · journal article · DOI 10.1093/asj/sjac296

Bibliografisk träff 2022-09-01

Human Kinase IGF1R/IR Inhibitor Linsitinib Controls the In Vitro and Intracellular Growth of <i>Mycobacterium tuberculosis</i>.

Wang H, Bi J, Zhang Y, Pan M, Guo Q, Xiao G, Cui Y, Hu S, Chan CK, Yuan Y, Kaneko T, Zhang G, Chen S.

ACS Infect Dis · research support, non-u.s. gov't; research-article; journal article · DOI 10.1021/acsinfecdis.2c00278

Bibliografisk träff 2022-01-04

OSI-906 restores the sensitivity of ovarian clear cell carcinoma to cisplatin by targeting the IGF1R/AKT pathway.

Liu L, Liang C, Zhuo C, Jiang H, Ye H, Ruan T, Song J, Jiang S, Zhang Y, Li X.

Med Oncol · journal article · DOI 10.1007/s12032-021-01592-w

Bibliografisk träff 2021-06-10

Autophagy induction by IGF1R inhibition with picropodophyllin and linsitinib.

Wu Q, Tian AL, Kroemer G, Kepp O.

Autophagy · article-commentary; research support, non-u.s. gov't; review; journal article · DOI 10.1080/15548627.2021.1936934

Bibliografisk träff 2021-05-27

Combination Treatment of OSI-906 with Aurora B Inhibitor Reduces Cell Viability via Cyclin B1 Degradation-Induced Mitotic Slippage.

Ikeda Y, Yasutake R, Yuki R, Saito Y, Nakayama Y.

Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms22115706

Bibliografisk träff 2021-01-28

A phase-1 trial of linsitinib (OSI-906) in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.

Khan S, LeBlanc R, Gyger M, White D, Kaufman J, Jazubowiak A, Gul E, Paul H, Le LW, Lau A, Li Z, Trudel S.

Leuk Lymphoma · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1080/10428194.2021.1876864

Bibliografisk träff 2020-12-11

Differential Effects of IGF-1R Small Molecule Tyrosine Kinase Inhibitors BMS-754807 and OSI-906 on Human Cancer Cell Lines.

Fuentes-Baile M, Ventero MP, Encinar JA, García-Morales P, Poveda-Deltell M, Pérez-Valenciano E, Barberá VM, Gallego-Plazas J, Rodríguez-Lescure Á, Martín-Nieto J, Saceda M.

Cancers (Basel) · research-article; journal article · DOI 10.3390/cancers12123717

Bibliografisk träff 2020-10-22

Linagliptin Ameliorates Hepatic Steatosis via Non-Canonical Mechanisms in Mice Treated with a Dual Inhibitor of Insulin Receptor and IGF-1 Receptor.

Okuyama T, Shirakawa J, Tajima K, Ino Y, Vethe H, Togashi Y, Kyohara M, Inoue R, Miyashita D, Li J, Goto N, Ichikawa T, Yamasaki S, Ohnuma H, Takayanagi R, Kimura Y, Hirano H, Terauchi Y.

Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms21217815

Bibliografisk träff 2020-01-03

Luseogliflozin increases beta cell proliferation through humoral factors that activate an insulin receptor- and IGF-1 receptor-independent pathway.

Shirakawa J, Tajima K, Okuyama T, Kyohara M, Togashi Y, De Jesus DF, Basile G, Kin T, Shapiro AMJ, Kulkarni RN, Terauchi Y.

Diabetologia · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1007/s00125-019-05071-w

Bibliografisk träff 2019-12-02

Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study.

von Mehren M, George S, Heinrich MC, Schuetze SM, Yap JT, Yu JQ, Abbott A, Litwin S, Crowley J, Belinsky M, Janeway KA, Hornick JL, Flieder DB, Chugh R, Rink L, Van den Abbeele AD.

Clin Cancer Res · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-19-1069

Bibliografisk träff 2019-08-21

Antitumor effect of insulin-like growth factor-1 receptor inhibition in head and neck squamous cell carcinoma.

Lehman CE, Khalil AA, Axelrod MJ, Dougherty MI, Schoeff SS, Taniguchi LE, Mendez RE, David AP, McGarey PO, Hubbard MA, Donaldson L, Frierson HF, Stelow EB, Bekiranov S, Wulfkuhle JD, Petricoin EF, Gioeli DG, Jameson MJ.

Laryngoscope · research support, non-u.s. gov't; journal article; research support, n.i.h., extramural · DOI 10.1002/lary.28236

Bibliografisk träff 2019-04-28

IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells.

Rodrigues Alves APN, Fernandes JC, Fenerich BA, Coelho-Silva JL, Scheucher PS, Simões BP, Rego EM, Ridley AJ, Machado-Neto JA, Traina F.

Cancer Lett · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1016/j.canlet.2019.04.030

Bibliografisk träff 2018-08-23

A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer.

Davis SL, Eckhardt SG, Diamond JR, Messersmith WA, Dasari A, Weekes CD, Lieu CH, Kane M, Choon Tan A, Pitts TM, Leong S.

Oncologist · research-article; clinical trial, phase i; journal article · DOI 10.1634/theoncologist.2018-0315

Bibliografisk träff 2018-02-23

A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC).

Barata P, Cooney M, Tyler A, Wright J, Dreicer R, Garcia JA.

Invest New Drugs · clinical trial, phase ii; journal article · DOI 10.1007/s10637-018-0574-0

Bibliografisk träff 2017-08-03

Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer.

Ciuleanu TE, Ahmed S, Kim JH, Mezger J, Park K, Thomas M, Chen J, Poondru S, VanTornout JM, Whitcomb D, Blackhall F.

Br J Cancer · clinical trial, phase ii; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1038/bjc.2017.226

Bibliografisk träff 2017-06-23

Metabolic recovery of lipodystrophy, liver steatosis, and pancreatic β cell proliferation after the withdrawal of OSI-906.

Tajima K, Shirakawa J, Togashi Y, Yamazaki S, Okuyama T, Kyohara M, Konishi H, Terauchi Y.

Sci Rep · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41598-017-04304-5

Bibliografisk träff 2016-11-16

Insulin-IGF signaling affects cell transformation in the BALB/c 3T3 cell model.

Poburski D, Leovsky C, Boerner JB, Szimmtenings L, Ristow M, Glei M, Thierbach R.

Sci Rep · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/srep37120

Bibliografisk träff 2016-09-30

A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer.

Chiappori AA, Otterson GA, Dowlati A, Traynor AM, Horn L, Owonikoko TK, Ross HJ, Hann CL, Abu Hejleh T, Nieva J, Zhao X, Schell M, Sullivan DM.

Oncologist · clinical trial, phase ii; comparative study; brief-report; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1634/theoncologist.2016-0220

Bibliografisk träff 2016-08-08

Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations.

Leighl NB, Rizvi NA, de Lima LG, Arpornwirat W, Rudin CM, Chiappori AA, Ahn MJ, Chow LQ, Bazhenova L, Dechaphunkul A, Sunpaweravong P, Eaton K, Chen J, Medley S, Poondru S, Singh M, Steinberg J, Juergens RA, Gadgeel SM.

Clin Lung Cancer · clinical trial, phase ii; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.cllc.2016.07.007

Bibliografisk träff 2016-02-01

Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.

Macaulay VM, Middleton MR, Eckhardt SG, Rudin CM, Juergens RA, Gedrich R, Gogov S, McCarthy S, Poondru S, Stephens AW, Gadgeel SM.

Clin Cancer Res · research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1158/1078-0432.ccr-15-2218

Bibliografisk träff 2015-03-18

Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study.

Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn DI, Hesseltine E, Ronchi CL, Terzolo M, Choueiri TK, Poondru S, Fleege T, Rorig R, Chen J, Stephens AW, Worden F, Hammer GD.

Lancet Oncol · clinical trial, phase iii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1016/s1470-2045(15)70081-1

Bibliografisk träff 2014-10-22

A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer.

Bendell JC, Jones SF, Hart L, Spigel DR, Lane CM, Earwood C, Infante JR, Barton J, Burris HA.

Invest New Drugs · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1007/s10637-014-0177-3

Bibliografisk träff 2014-04-12

Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance.

Zhang H, Kathawala RJ, Wang YJ, Zhang YK, Patel A, Shukla S, Robey RW, Talele TT, Ashby CR, Ambudkar SV, Bates SE, Fu LW, Chen ZS.

Int J Biochem Cell Biol · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.biocel.2014.03.026

Bibliografisk träff 2010-06-08

Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development.

Pitts TM, Tan AC, Kulikowski GN, Tentler JJ, Brown AM, Flanigan SA, Leong S, Coldren CD, Hirsch FR, Varella-Garcia M, Korch C, Eckhardt SG.

Clin Cancer Res · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-09-3191